Data / Research funding / Topical Microbicides
Topical Microbicides: 67 NIH awards ($390.5M) to 38 organizations
67 NIH awards ($390.5M) in the NIH spending category Topical Microbicides, to 38 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
67 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| HIV Prevention Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $213,590,410 | June 1, 2006 | November 30, 2027 | COHEN, MYRON SCOTT | reporter.nih.gov |
| UZ-UCSF CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,624,239 | September 9, 2025 | November 30, 2027 | CHIRENJE, ZVAVAHERA MIKE | reporter.nih.gov |
| Pitt-Ohio State Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,065,770 | February 1, 2007 | November 30, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| Reagent Resource Support Program for AIDS Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,522,629 | April 8, 2018 | April 7, 2025 | FREMONT, VALERIE | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| San Francisco Bay Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,314,128 | March 2, 2007 | November 30, 2027 | BUCHBINDER, SUSAN | reporter.nih.gov |
| Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $8,076,617 | July 15, 2022 | July 14, 2023 | SILVERA, PETER | reporter.nih.gov |
| Aurum Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,678,965 | December 1, 2020 | November 30, 2027 | CHURCHYARD, GAVIN JOHN | reporter.nih.gov |
| Stellenbosch University Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,524,563 | April 15, 2007 | November 30, 2027 | HESSELING, ANNEKE CATHARINA | reporter.nih.gov |
| Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $4,955,441 | September 21, 2019 | August 31, 2025 | JANUSZIEWICZ, RIMA | reporter.nih.gov |
| The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuum | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $4,640,955 | September 30, 2016 | November 30, 2022 | HIGHTOW-WEIDMAN, LISA B | reporter.nih.gov |
| Ultra-Long-Acting Polymeric Injectable Multi-Purpose Prevention Technology for Contraception and HIV Prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,740,241 | April 13, 2021 | March 31, 2027 | BENHABBOUR, SOUMYA RAHIMA | reporter.nih.gov |
| An Etonogestrel/Ethinyl Estradiol/QGriffithsin (ETG/EE/QGRFT) IVR to Prevent Pregnancy and HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,644,121 | April 6, 2020 | August 31, 2025 | TELESHOVA, NATALIA | reporter.nih.gov |
| Novel pre-coital, non-hormonal multipurpose prevention technology (MPT) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,585,858 | March 20, 2020 | February 28, 2026 | ANGSANTIKUL, PAVIMOL | reporter.nih.gov |
| A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,558,948 | August 28, 2020 | July 31, 2025 | MOSS, JOHN A | reporter.nih.gov |
| Statistical and Data Management Center (SDMC): Microbicide Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $3,470,954 | June 29, 2006 | November 30, 2021 | BROWN, ELIZABETH RENATA | reporter.nih.gov |
| Next Generation Multipurpose Intravaginal Ring Technology Using Innovative CLIP 3D Printing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,269,405 | December 1, 2019 | November 30, 2025 | BENHABBOUR, SOUMYA RAHIMA | reporter.nih.gov |
| Leadership and Operations Center (LOC): Microbicide Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $3,164,556 | June 29, 2006 | November 30, 2021 | HILLIER, SHARON L. | reporter.nih.gov |
| ACTION: Study of ACuTe Infections On Novel HIV Prevention Modalities | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,134,333 | July 1, 2022 | June 30, 2027 | KOSS, CATHERINE ANNE STIMETS | reporter.nih.gov |
| IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,050,000 | February 1, 2018 | August 31, 2027 | SMITH, THOMAS J. | reporter.nih.gov |
| 3D-bioprinting of sustained- and phased-release antibiotic and probiotic scaffolds to treat bacterial vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,595 | February 25, 2022 | January 31, 2028 | FRIEBOES, HERMANN | reporter.nih.gov |
| Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,960,837 | May 5, 2020 | February 28, 2026 | BAUM, MARC MICHAEL | reporter.nih.gov |
| A low-profile copper intrauterine device that delivers long-acting contraception an | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,953,397 | September 16, 2020 | August 31, 2025 | WOODROW, KIM A. | reporter.nih.gov |
| Durable Vaginal Protection from HIV via mRNA expression of BNABS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,806,701 | September 16, 2020 | August 31, 2026 | SANTANGELO, PHILIP J | reporter.nih.gov |
| Long-acting multi prevention implant for 2-year contraception and HIV PrEP | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,464,240 | April 1, 2023 | March 31, 2028 | GRATTONI, ALESSANDRO | reporter.nih.gov |
| SMART Polymer Fibers For Tampon-Like Nonsteroidal Contraceptive Devices | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $2,377,574 | September 13, 2019 | August 31, 2025 | PAULETTI, GIOVANNI M | reporter.nih.gov |
| Laboratory Center (LC): Microbicide Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,058,087 | January 1, 2014 | November 30, 2021 | ROHAN, LISA CENCIA | reporter.nih.gov |
| Phase 2 placebo-controlled randomized trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $2,007,226 | June 12, 2019 | March 31, 2025 | COHEN, CRAIG R | reporter.nih.gov |
| Effectiveness of PrEP product choice on HIV prevention coverage among young women in Kenya seeking reproductive health services | NIH | National Institute of Mental Health | 2023 to 2025 | $1,854,463 | September 14, 2023 | July 31, 2028 | HEFFRON, RENEE A. | reporter.nih.gov |
| Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,702,035 | April 1, 2021 | March 31, 2024 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| A Novel, Multi-compartment Intravaginal Ring for Prevention of Genital Herpes and Unintended Pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,670,110 | September 10, 2024 | July 31, 2029 | BAUM, MARC MICHAEL | reporter.nih.gov |
| Understanding the Host-Microbiome-Therapeutic Triad: Implications for Designing Alternative Intravaginal Delivery Platforms to Treat Bacterial Vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,539,804 | July 5, 2019 | June 30, 2025 | FRIEBOES, HERMANN | reporter.nih.gov |
| Impact of the vaginal microbiome on topical HIV pre-exposure prophylaxis (PrEP) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,533,887 | April 12, 2019 | March 31, 2025 | HEROLD, BETSY C. | reporter.nih.gov |
| Phase 1 Randomized Double-Blind Placebo-Controlled Safety Study of MucoCept-CVN (Lactobacillus jensenii 1153-1666) Administered Vaginally to Healthy Women | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,533,177 | November 22, 2024 | October 31, 2027 | HEMMERLING, ANKE | reporter.nih.gov |
| Immunologic changes associated with three progestin-based contraceptives: characterizing immune profiles over one year and identifying factors that may alter HIV risk | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,507,492 | August 1, 2018 | June 30, 2025 | SMITH, ALICIA K | reporter.nih.gov |
| Synthesis of Therapeutic Agents for Treatment of Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,356,473 | February 16, 2015 | February 15, 2019 | MIDDLETON, MARK | reporter.nih.gov |
| Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,188,509 | September 24, 2018 | June 15, 2023 | GARCIA-MARTINEZ, J. VICTOR | reporter.nih.gov |
| Improving PrEP outcomes among pregnant women in Botswana with an integrated STI testing and PrEP delivery model | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,129,420 | September 2, 2024 | August 31, 2029 | MORRONI, CHELSEA | reporter.nih.gov |
| Project Horizon: Hydrogel Injectable Depot System for Next-Generation Long-Acting HIV Prevention and Contraception | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,052,953 | February 12, 2019 | January 31, 2022 | CLARK, MEREDITH R | reporter.nih.gov |
| IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,025,000 | June 23, 2025 | May 31, 2028 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Advancing pharmacy-based delivery of primary STI and HIV prevention for cisgender women | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $985,308 | September 1, 2025 | May 31, 2030 | PINTYE, JILLIAN | reporter.nih.gov |
| IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $922,634 | April 1, 2018 | March 31, 2023 | SMITH, THOMAS J. | reporter.nih.gov |
| "Hair Extensions": Using Hair Levels to Interpret Adherence, Effectiveness and Pharmacokinetics with Real-World Oral PrEP, the Vaginal Ring, and Injectables | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $756,997 | December 15, 2011 | January 31, 2023 | GANDHI, MONICA | reporter.nih.gov |
| Expanded Safety and Preliminary Efficacy of Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women with HIV in Africa | NIH | National Cancer Institute | 2025 | $688,458 | September 15, 2025 | August 31, 2030 | MUNGO, CHEMTAI | reporter.nih.gov |
| Prevention of HIV-1 transmission by small-molecule CD4-mimetic entry inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $651,658 | July 14, 2017 | June 30, 2024 | MADANI, NAVID | reporter.nih.gov |
| The impact of vaginal microbiota on cervical dendritic cells: an observational study of women from sub-Saharan Africa at high risk for HIV acquisition. | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $643,248 | April 15, 2020 | March 31, 2026 | SABO, MICHELLE CATHERINE | reporter.nih.gov |
| Transfer, Validation and Qualification of Bioanalytical Methods for Detection of Cabotegravir and Levonorgestrel in Rat and Nonhuman Primate Plasma | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $625,408 | November 14, 2024 | November 14, 2025 | KUEHL, PHILIP | reporter.nih.gov |
| Bispecific antibody for topical administration to prevent gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $599,998 | August 1, 2024 | July 31, 2027 | WYCOFF, KEITH | reporter.nih.gov |
| The impact of HIV on accelerated aging in the female genital tract: a pilot trial of topical estradiol to improve the vaginal microbiome and symptoms of vaginal atrophy in menopausal women with HIV | NIH | National Institute on Aging | 2021 to 2023 | $592,920 | February 1, 2020 | January 31, 2025 | MURPHY, KERRY JEANNE | reporter.nih.gov |
| Simian Vaccine Evaluation Unit (SVEU) - Animal Maintenance and Care | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $549,792 | May 1, 2016 | April 30, 2019 | WEISS, DEBORAH | reporter.nih.gov |
| NICHD SERVICES: Multipurpose Prevention Technologies (MPT) DATABASE ACCESS AND MAINTENANCE for Contraceptive Research | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $535,124 | September 27, 2024 | September 26, 2026 | YOUNG HOLT, BETHANY | reporter.nih.gov |
| Development of a bioadhesive vaginal film for extended release of MPT antibodies | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $518,754 | February 1, 2025 | March 14, 2026 | ROHAN, LISA CENCIA | reporter.nih.gov |
| Mitigating sexual stigma within healthcare interactions to improve engagement of MSM in HIV prevention | NIH | National Institute of Mental Health | 2023 to 2025 | $499,787 | January 1, 2021 | December 31, 2026 | KUTNER, BRYAN A. | reporter.nih.gov |
| The vaginal microenvironment in asymptomatic versus symptomatic bacterial vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $482,097 | March 1, 2023 | February 28, 2026 | TUDDENHAM, SUSAN ANNE | reporter.nih.gov |
| Cervical Cancer Prevention Prebiotic Device | NIH | National Cancer Institute | 2021 to 2022 | $454,968 | March 15, 2022 | June 14, 2022 | ELLINGTON, JOANNA ELIZABETH | reporter.nih.gov |
| The Impact of Testosterone Use on the Vaginal Microbiota in Transgender Men, including Susceptibility to Bacterial Vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $438,964 | November 1, 2021 | October 31, 2024 | MUZNY, CHRISTINA A | reporter.nih.gov |
| A novel, non-hormonal, long-acting female contraceptive device | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $383,114 | September 13, 2024 | August 31, 2025 | MAN, EMILY | reporter.nih.gov |
| Exploring synergies in pharmacy-based delivery of PrEP and contraception for adolescent girls and young women in Kenya | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $359,992 | September 11, 2024 | August 31, 2026 | HARRINGTON, ELIZABETH K | reporter.nih.gov |
| Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $310,136 | August 21, 2025 | July 31, 2027 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Vaginal ring for sustained release of lactic acid to prevent bacterial vaginosis and associated health risks | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $306,500 | March 1, 2021 | February 28, 2023 | CONE, RICHARD | reporter.nih.gov |
| Fast dissolving antibody tablets for preventing vaginal HSV transmission | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $306,500 | September 1, 2022 | August 31, 2024 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Highly Acidifying Intravaginal Rings with Lactobacillus Probiotics to Treat Bacterial Vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $306,483 | April 1, 2023 | March 31, 2025 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Small Molecule E6 Inhibitors to Treat Dysplasia Caused by HPV Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $298,527 | July 1, 2022 | March 31, 2024 | LU, ZHIJIAN | reporter.nih.gov |
| Preparation and submission of an IND for PPCM Gel contraceptive | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 | $298,521 | April 6, 2022 | March 31, 2023 | WEITZEL, MARY B | reporter.nih.gov |
| Multipurpose vaginal ring for non-hormonal contraception and preventing bacterial vaginosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $265,970 | August 1, 2021 | July 31, 2023 | CONE, RICHARD | reporter.nih.gov |
| Perceptions of Multipurpose Prevention Technologies Aimed at HIV/STI/unintended pregnancy among African-American Women in the Deep South | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $139,486 | November 1, 2020 | October 31, 2024 | TYMES-WILBEKIN, KRISTINA AYANNA | reporter.nih.gov |
| Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $126,371 | February 1, 2019 | February 28, 2024 | RICCIO, DANIEL | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Family Health International | Durham, NC | 1 | $213.6 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 5 | $29.1 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 5 | $13.5 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 1 | $13.1 million | 0 | $0 |
| Quality Biological, Inc. | Gaithersburg, MD | 1 | $11.5 million | 0 | $0 |
| Chiang Mai University | Chiang Mai | 1 | $10.1 million | 0 | $0 |
| Public Health Foundation Enterprises | City Of Industry, CA | 1 | $8.3 million | 0 | $0 |
| Oak Crest Institute of Science | Monrovia, CA | 3 | $8.2 million | 0 | $0 |
| Advanced Bioscience Laboratories, Inc. | Kensington, MD | 1 | $8.1 million | 0 | $0 |
| Population Council | New York, NY | 2 | $7.2 million | 0 | $0 |
| Aurum Institute NPC | Parktown, Johannesburg | 1 | $6.7 million | 0 | $0 |
| Stellenbosch University | Stellenbosch | 1 | $6.5 million | 0 | $0 |
| Magee-Women's Res Inst and Foundation | Pittsburgh, PA | 3 | $5.7 million | 0 | $0 |
| Anelleo, Inc. | Chapel Hill, NC | 1 | $5 million | 0 | $0 |
| University of Washington | Seattle, WA | 4 | $4.9 million | 0 | $0 |
| University of Louisville | Louisville, KY | 2 | $4.6 million | 0 | $0 |
| Emory University | Atlanta, GA | 2 | $4.3 million | 0 | $0 |
| Mucommune, LLC | Morrisville, NC | 7 | $4.2 million | 0 | $0 |
| Auritec Pharmaceuticals, Inc. | Pasadena, CA | 2 | $4 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 1 | $3.5 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 3 | $2.6 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 1 | $2.5 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 3 | $2.4 million | 0 | $0 |
| ST. Louis College of Pharmacy | St. Louis, MO | 1 | $2.4 million | 0 | $0 |
| Starks Associates, Inc. | Buffalo, NY | 1 | $1.4 million | 0 | $0 |
| The Botswana Harvard Health Partnership | Gaborone | 1 | $1.1 million | 0 | $0 |
| Eastern Virginia Medical School | Norfolk, VA | 1 | $1.1 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 1 | $651,658 | 0 | $0 |
| Lovelace Biomedical Research Institute | Albuquerque, NM | 1 | $625,408 | 0 | $0 |
| Planet Biotechnology, Inc. | Hayward, CA | 1 | $599,998 | 0 | $0 |
| Bioqual, Inc. | Rockville, MD | 1 | $549,792 | 0 | $0 |
| Public Health Institute | Oakland, CA | 1 | $535,124 | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 1 | $482,097 | 0 | $0 |
| Glyciome, LLC | Valleyford, WA | 1 | $454,968 | 0 | $0 |
| Venova Technologies, Inc. | Cambridge, MA | 1 | $383,114 | 0 | $0 |
| Kovina Therapeutics Inc. | Indianapolis, IN | 1 | $298,527 | 0 | $0 |
| Yaso Therapeutics INC | Fate, TX | 1 | $298,521 | 0 | $0 |
| Novan, Inc. | Durham, NC | 1 | $126,371 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 28 | $52,916,183 | 0 | $0 |
| 2024 | 34 | $55,822,541 | 0 | $0 |
| 2023 | 36 | $55,898,008 | 0 | $0 |
| 2022 | 39 | $78,017,177 | 0 | $0 |
| 2021 | 40 | $147,835,787 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 39 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 39 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 39 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.